B-progenitor acute lymphoblastic leukemia (B-ALL) is the commonest childhood malignancy and remains a leading cause of death in children and young adults. Current therapeutic approaches involve intensive combination chemotherapy, which fail in up to one-quarter of patients. New treatment approaches directed against rational therapeutic targets are required. Recent genomic profiling of ALL has identified several genetic alterations associated with a high risk of treatment failure. Deletion or sequence mutation of the lymphoid transcription factor gene IKZF1 (IKAROS) is associated is associated with a high rate of leukemic relapse, and testing for IKZF1 alterations at diagnosis may aid risk stratification. A subset of B-ALL patients with IKZF1 alterations have a transcriptional profile similar to BCR-ABL1 positive ALL, and these patients commonly have novel rearrangements and mutations resulting in aberrant cytokine receptor signaling and activation of kinase signaling cascades, including rearrangement of CRLF2 and activating mutations of Janus kinases (JAK1 and JAK2). JAK inhibitor therapy is under investigation in children with relapsed and refractory malignancies, including leukemia.
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On the Horizon
Several centers in the US and Europe have performed genomic profiling of B-progenitor ALL and identified novel genetic alterations associated with high risk disease (5) (6) (7) (8) (9) (10) (11) (12) . In general, these studies have profiled leukemic cells obtained at diagnosis. Most of these studies have used microarray-based approaches to profile structural genetic alterations, gene expression profiling, as well as selective sequencing of individual genes. While informative, it should be emphasized that microarray approaches do not directly identify chromosomal rearrangements or tumor-acquired sequence mutations. Consequently, there is currently intense interest in the use of next-generation sequencing technology to comprehensively identify sequence alterations (13) and rearrangements (14) ¸ but at present these have not been widely deployed in ALL.
B-lineage ALL
Microarray profiling of structural genetic alterations, including deletions and gains of DNA (DNA copy number abnormalities, or CNA) and copy-neutral loss-of-heterozygosity (LOH) have identified multiple recurring submicroscopic genetic alterations in ALL (reviewed in ref.
(15)). In contrast to the genomes of many solid tumors, which commonly harbor multiple large genetic alterations (16) , most ALL samples have relatively few alterations, and those observed are commonly focal and limited to one or few genes (5, 9, 10 and a subset of ALL (Ph+ ALL). Prior to the advent of tyrosine kinase inhibitors (TKIs) such as imatinib, BCR-ABL1 positive ALL was associated with very poor outcome (24) , and the reasons why BCR-ABL1 resulted in two such distinct diseases has been poorly understood. IKZF1 alterations are present in over 80% of Ph+ ALL cases in both adults and children, and at the progression of chronic myeloid leukemia (CML) to lymphoid blast crisis, but not in CML at chronic phase (7, 25) . Moreover, alterations of IKZF1 are associated with poor outcome in adult Ph+ ALL (26) . IKZF1 alterations are uncommon in other subtypes of ALL that otherwise harbor multiple DNA copy number alterations, such as ETV6-RUNX1 ALL (6, 27) . This suggests that IKZF1 alteration is a key determinant of the lineage and progression of Ph+ leukemia.
IKZF1 deletion or sequence mutation is also associated with poor outcome in Ph-ALL, at least in children (7, 11, 12) . Fifteen to thirty percent of B-ALL cases have deletion of IKZF1, and less commonly deleterious sequence mutations. Mutation of IKZF1 is associated with an up to three-fold increased risk of treatment failure in ALL (7, 11) . In a multivariable analysis of established prognostic factors including age, sex, presentation peripheral blood leukocyte count and cytogenetic subtype, IKZF1 status was independently associated with poor outcome.
Consequently, there has been considerable interest in testing for IKZF1 alterations at the time of Routine diagnostic microarray profiling of DNA CNA in ALL is becoming increasingly widely used, either using oligonucleotide array-based comparative genomic hybridization (array-CGH) or single nucleotide polymorphism microarrays (SNP arrays). Data from these arrays must be analyzed and interpreted with great care, as several array platforms, even those with hundreds of thousands of features, lack sufficient resolution to detect very focal IKZF1 alterations.
Alternative approaches include customized arrays, genomic quantitative PCR (6), multiplex ligation-dependent probe amplification (MLPA) (28) , and sequence mutation screening methods.
Genomic profiling has also identified potential therapeutic targets in high-risk ALL (Table   1) Microarray-based profiling of high-risk B-progenitor ALL has proven exceptionally informative in identifying novel genetic alterations associated with poor outcome, and in defining new subtypes of ALL harboring previously unrecognized genetic alterations. Continued efforts to identify additional genetic alterations, however, are required. Up to one-half of patients with CRLF2 alterations lack a JAK mutation, and the nature of the additional mutation(s) in these cases is unknown. Moreover, many Ph-like cases lack a CRLF2 alteration; many IKZF1-mutated cases are not Ph-like but fail therapy; and a substantial proportion of ALL cases lack IKZF1 alteration and/or a known chromosomal rearrangement. Importantly, the frequency of cases lacking known genetic alterations rises, and outcome declines with increasing age (4, 36, 37) . Thus, detailed analysis of these cases is required to identify additional prognostic markers
Research. and targets for therapy. It is also likely that the limits of microarray-based technology are being reached, and that next-generation sequencing based approaches will be required to comprehensively identify all sequence variations and structural rearrangements in ALL. The potential utility of these approaches has been identified in both B-ALL and T-lineage ALL.
In a study of high-risk B-ALL cases, transcriptomic resequencing (RNA-seq) was performed using the Illumina GAIIx platform. This identified rearrangements not previously identified in B-ALL, including the NUP214-ABL1 fusion previously described in T-lineage ALL, and a novel rearrangement, STRN3-JAK2 (14) . These findings are clinically relevant, as both these rearrangements are known or predicted to result in constitutive kinase activation, and are potentially amenable to TKI therapy.
T-lineage ALL
T-ALL is less common than B-progenitor childhood ALL, but has an inferior outcome to B-ALL (38) . Genomic profiling has also been successfully used to identify new structural and sequence alterations in T-ALL, including deletions dysregulating LMO2 (39), amplification of MYB (40, 41) , amplification associated with the NUP214-ABL1 rearrangement (42), and deletion and sequence mutation of PTEN (43) and WT1 (44) . A notable recent study utilized exon capture and next-generation sequencing of X chromosome genes and identified common mutations in PHF6 in childhood and adult T-ALL (13) . However, few associations between individual genetic alterations and outcome in T-ALL have been identified.
Recently, a subtype of T-ALL has been described with an immature immunophenotype similar to that of early thymic progenitors (ETP). These cases have absent CD1a or CD8 expression, weak or absent CD5 expression, aberrant expression of myeloid and stem cell markers, and a distinct gene expression signature (45, 46) . These "ETP T-ALL" cases have poor responsiveness to initial therapy (as evidenced by high levels of minimal residual disease) and very poor outcome, and detection of the ETP immunphenotype is being utilized to identify these patients and intervene with aggressive therapies, such as bone marrow transplantation.
ETP T-ALL leukemic cells commonly have a high burden of genomic alterations, but at present the underlying genetic lesion(s) have not been identified.
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